Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition Dec 13, 2021
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition Dec 8, 2021
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors Nov 16, 2021
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update Nov 8, 2021
Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies Oct 25, 2021
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer Sep 22, 2021
